Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

SINOVAC BIOTECH LTD.

(SVA)
  Report
SummaryQuotesChartsNewsCalendarCompanyFinancials 
SummaryMost relevantAll NewsOther languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Sinovac Biotech : Antibodies from Sinovac's COVID-19 shot fade after about 6 months, booster helps - study

07/26/2021 | 10:25am EDT

BEIJING, July 26 (Reuters) - Antibodies triggered by Sinovac Biotech's COVID-19 vaccine decline below a key threshold from around six months after a second dose for most recipients, although a third shot could have a strong boosting effect, according to a lab study.

Chinese researchers reported the findings from a study of blood samples from healthy adults aged between 18-59 in a paper published on Sunday, which has not been peer reviewed.

For participants receiving two doses, two or four weeks apart, only 16.9% and 35.2% respectively still had a level of neutralising antibodies above the threshold six months after the second dose, the paper said.

Those readings was based on data from two cohorts involving more than 50 participants each, while the study gave third doses to a total of 540 participants.

When participants in some cohorts were given a third dose, about six months after the second, neutralising antibody levels after a further 28 days had increased around 3-5 fold from the levels seen four weeks after the second dose, the study showed.

The study was conducted by researchers at disease control authorities in Jiangsu province, Sinovac, and other Chinese institutions.

Researchers cautioned the study did not test the antibodies' effect against more transmissible variants, and that further research was needed to assess antibody duration after a third shot. (Reporting by Roxanne Liu and Ryan Woo Editing by Mark Potter)


ę Reuters 2021
All news about SINOVAC BIOTECH LTD.
09/24CANSINO BIOLOGICS : CanSinoBIO's COVID vaccine, tested at lower dosage, safe for children ..
RE
09/22SINOVAC BIOTECH : Thailand delays plan to re-open cities to tourists until November
RE
09/15INDONESIA IN TALKS WITH WHO TO BECOM : minister
RE
09/09SINOVAC BIOTECH : Says its New Research Shows Third Dose if its COVID-19 Vaccine More Effe..
MT
09/09SINOVAC BIOTECH : New Research on SINOVAC's COVID-19 Vaccine Shows Third Dose More Effecti..
BU
09/08SINOVAC BIOTECH : Announces COVID-19 Vaccine Approved for Emergency Use in Chile for Child..
BU
09/07SINOVAC BIOTECH : Mixing CanSinoBIO, Sinovac COVID shots induces stronger response than Si..
RE
09/01SINOVAC BIOTECH : North Korea turns down Sinovac COVID-19 vaccine doses - WSJ
RE
08/24SINOVAC BIOTECH : COVID-19 booster shots should follow after China inoculates more -state ..
RE
08/23São Paulo City Will Require Proof of Vaccination to Enter Shops, Bars
DJ
More news
Financials (USD)
Sales 2020 511 M - -
Net income 2020 110 M - -
Net cash 2020 1 040 M - -
P/E ratio 2020 6,66x
Yield 2020 -
Capitalization 642 M 642 M -
EV / Sales 2019 1,86x
EV / Sales 2020 -0,78x
Nbr of Employees 1 959
Free-Float 33,5%
Chart SINOVAC BIOTECH LTD.
Duration : Period :
Sinovac Biotech Ltd. Technical Analysis Chart | MarketScreener
Full-screen chart
Income Statement Evolution
Managers and Directors
Wei Dong Yin Chairman, President, CEO, Secretary & MD
Nan Wang CFO & Vice President-Business Development
Qiang Gao Chief Operating Officer & Vice President
Yuk Lam Lo Independent Director
Jian Li Independent Director
Sector and Competitors
1st jan.Capi. (M$)
SINOVAC BIOTECH LTD.0.00%642
CSL LIMITED10.18%103 032
WUXI BIOLOGICS (CAYMAN) INC.14.59%64 160
SAMSUNG BIOLOGICS CO.,LTD.11.62%51 643
BIOGEN INC.19.13%43 475
ALEXION PHARMACEUTICALS, INC.0.00%40 336